Bionure
Late-preclinical company focused at developing first-in-class sgk agonists for the treatment of rare ophthalmology diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€17—26m (Dealroom.co estimates May 2018.)
Company register number B67600346
Barcelona Catalonia (HQ)
Authorizing premium user...